Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma
Abstract Elranatamab, an approved bispecific antibody (BsAb) for relapsed/refractory multiple myeloma, forms an immune synapse between the T-cell CD3 marker and B-cell maturation antigen (BCMA) on myeloma cells. Circulating soluble BCMA (sBCMA) is associated with disease burden and may reduce drug e...
שמור ב:
| Principais autores: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Portfolio
2025-09-01
|
| סדרה: | npj Systems Biology and Applications |
| גישה מקוונת: | https://doi.org/10.1038/s41540-025-00585-z |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|